Spring til hovednavigation
Spring til søgning
Spring til hovedindhold
Region Hovedstadens forskningsportal Forside
Hjælp og OSS
Dansk
English
Forside
Hospitaler/afdelinger
Forskere
Publikationer
Aktiviteter
Priser
Søg efter ekspertise, navn eller tilknytning
Early safety and efficacy of fingolimod treatment in Denmark
A Voldsgaard, N Koch-Henriksen,
M Magyari
,
F Sellebjerg
,
P S Sørensen
, A B Oturai
Afdeling for Hjerne- og Nervesygdomme NEU
13
Citationer (Scopus)
Oversigt
Fingeraftryk
Fingeraftryk
Dyk ned i forskningsemnerne om 'Early safety and efficacy of fingolimod treatment in Denmark'. Sammen danner de et unikt fingeraftryk.
Sorter
Vægt
Alfabetisk
Keyphrases
Denmark
100%
Fingolimod
100%
Early Efficacy
100%
Early Safety
100%
Adverse Effects
33%
MS Patients
33%
Treatment Initiation
16%
Clinical Trials
16%
Clinical Setting
16%
Heart Rate
16%
Natalizumab
16%
Interferon-β (IFN-β)
16%
Annualized Relapse Rate
16%
Therapeutic Effect
16%
Bradycardia
16%
Second-degree Atrioventricular Block
16%
Prolonged Cardiac Monitoring
16%
Block Type
16%
Respiratory Complaints
16%
Atrioventricular Conduction Disturbance
16%
Therapeutic Safety
16%
Pharmacology, Toxicology and Pharmaceutical Science
Fingolimod
100%
Adverse Event
33%
Side Effect
16%
Recurrence Risk
16%
Clinical Trial
16%
Natalizumab
16%
Therapeutic Effect
16%
Second Degree Atrioventricular Block
16%